2024-517752-35-00招募中1 期
A phase I study of the mesothelin x CD47 antibody NI-1801, as a single agent and in combination with Anti-PD-1 antibody, or with paclitaxel in solid cancers
NovImmune S.A.8 个研究点 分布在 3 个国家目标入组 82 人开始时间: 2024年11月5日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 82
- 试验地点
- 8
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Jose Saro
Scientific
NovImmune S.A.
研究点 (8)
Loading locations...
相似试验
招募中
1 期
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaRelapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042971Term: T-cell lymphoma Class: 100000004864CTIS2023-508355-39-00Ospedale Pediatrico Bambino Gesu'26
已完成
不适用
Alemtuzumab, MabCampath® with 2-weekly CHOP chemotherapy for mature T-cell non-Hodgkin's lymphomaMature T-cell non-Hodgkin's lymphomaCancerOther and unspecified types of non-Hodgkin's lymphomaISRCTN52265296Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)20
已完成
1 期
A Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects with Advanced Solid TumorsAdvanced solid tumorsJPRN-jRCT2031200341Guseva Maria190
已完成
2 期
An phase I study of BI 765063 (a monoclonal antibody) as single agent and in combination with BI 754091 (a PD-1) to characterize safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in patients with advanced solid tumour2024-519150-37-00OSE Immunotherapeutics, OSE Immunotherapeutics78
进行中（未招募）
不适用
Clinical Study of Antibodies to Shiga Toxins 1 and 2Prevention of Shiga toxin-mediated complications resulting from Shiga toxin producing bacterial infections.MedDRA version: 14.1Level: LLTClassification code 10019515Term: Hemolytic uremic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-006094-26-Outside-EU/EEAThallion Pharmaceuticals Inc42